Literature DB >> 22610453

Presence versus absence of hydrogen bond donor Tyr-39 influences interactions of cationic trypsin and mesotrypsin with protein protease inhibitors.

Moh'd A Salameh1, Alexei S Soares, Alexandre Alloy, Evette S Radisky.   

Abstract

Mesotrypsin displays unusual resistance to inhibition by polypeptide trypsin inhibitors and cleaves some such inhibitors as substrates, despite a high degree of conservation with other mammalian trypsins. Substitution of Arg for the generally conserved Gly-193 has been implicated as a critical determinant of the unusual behavior of mesotrypsin toward protein protease inhibitors. Another relatively conserved residue near the trypsin active site, Tyr-39, is substituted by Ser-39 in mesotrypsin. Tyr-39, but not Ser-39, forms a hydrogen bond with the main chain amide nitrogen of the P(4) ' residue of a bound protease inhibitor. To investigate the role of the Tyr-39 H-bond in trypsin-inhibitor interactions, we reciprocally mutated position 39 in mesotrypsin and human cationic trypsin to Tyr-39 and Ser-39, respectively. We assessed inhibition constants and cleavage rates of canonical protease inhibitors bovine pancreatic trypsin inhibitor (BPTI) and the amyloid precursor protein Kunitz protease inhibitor domain by mesotrypsin and cationic trypsin variants, finding that the presence of Ser-39 relative to Tyr-39 results in a 4- to 13-fold poorer binding affinity and a 2- to 18-fold increase in cleavage rate. We also report the crystal structure of the mesotrypsin-S39YBPTI complex, in which we observe an H-bond between Tyr-39 OH and BPTI Ile-19 N. Our results indicate that the presence of Ser-39 in mesotrypsin, and corresponding absence of a single H-bond to the inhibitor backbone, makes a small but significant functional contribution to the resistance of mesotrypsin to inhibition and the ability of mesotrypsin to proteolyze inhibitors.
Copyright © 2012 The Protein Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22610453      PMCID: PMC3537232          DOI: 10.1002/pro.2097

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  37 in total

Review 1.  Natural protein proteinase inhibitors and their interaction with proteinases.

Authors:  W Bode; R Huber
Journal:  Eur J Biochem       Date:  1992-03-01

2.  Coot: model-building tools for molecular graphics.

Authors:  Paul Emsley; Kevin Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-11-26

3.  Likelihood-enhanced fast translation functions.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Laurent C Storoni; Randy J Read
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2005-03-24

4.  Structural and mutational analyses of the molecular interactions between the catalytic domain of factor XIa and the Kunitz protease inhibitor domain of protease nexin 2.

Authors:  Duraiswamy Navaneetham; Lei Jin; Pramod Pandey; James E Strickler; Robert E Babine; Sherin S Abdel-Meguid; Peter N Walsh
Journal:  J Biol Chem       Date:  2005-08-06       Impact factor: 5.157

Review 5.  Activation of pancreatic zymogens. Normal activation, premature intrapancreatic activation, protective mechanisms against inappropriate activation.

Authors:  H Rinderknecht
Journal:  Dig Dis Sci       Date:  1986-03       Impact factor: 3.199

Review 6.  Structural basis of substrate specificity in the serine proteases.

Authors:  J J Perona; C S Craik
Journal:  Protein Sci       Date:  1995-03       Impact factor: 6.725

7.  Identification and expression of the cDNA-encoding human mesotrypsin(ogen), an isoform of trypsin with inhibitor resistance.

Authors:  C N Nyaruhucha; M Kito; S I Fukuoka
Journal:  J Biol Chem       Date:  1997-04-18       Impact factor: 5.157

8.  Activity of recombinant trypsin isoforms on human proteinase-activated receptors (PAR): mesotrypsin cannot activate epithelial PAR-1, -2, but weakly activates brain PAR-1.

Authors:  Zoryana Grishina; Ewa Ostrowska; Walter Halangk; Miklós Sahin-Tóth; Georg Reiser
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

9.  Mesotrypsin: a new inhibitor-resistant protease from a zymogen in human pancreatic tissue and fluid.

Authors:  H Rinderknecht; I G Renner; S B Abramson; C Carmack
Journal:  Gastroenterology       Date:  1984-04       Impact factor: 22.682

10.  Characterization of human exocrine pancreatic proteins by two-dimensional isoelectric focusing/sodium dodecyl sulfate gel electrophoresis.

Authors:  G Scheele; D Bartelt; W Bieger
Journal:  Gastroenterology       Date:  1981-03       Impact factor: 22.682

View more
  12 in total

Review 1.  Biochemical and structural insights into mesotrypsin: an unusual human trypsin.

Authors:  Moh'd A Salameh; Evette S Radisky
Journal:  Int J Biochem Mol Biol       Date:  2013-09-13

2.  Mesotrypsin Has Evolved Four Unique Residues to Cleave Trypsin Inhibitors as Substrates.

Authors:  Alexandre P Alloy; Olumide Kayode; Ruiying Wang; Alexandra Hockla; Alexei S Soares; Evette S Radisky
Journal:  J Biol Chem       Date:  2015-07-14       Impact factor: 5.157

3.  An Acrobatic Substrate Metamorphosis Reveals a Requirement for Substrate Conformational Dynamics in Trypsin Proteolysis.

Authors:  Olumide Kayode; Ruiying Wang; Devon F Pendlebury; Itay Cohen; Rachel D Henin; Alexandra Hockla; Alexei S Soares; Niv Papo; Thomas R Caulfield; Evette S Radisky
Journal:  J Biol Chem       Date:  2016-11-03       Impact factor: 5.157

4.  Pre-equilibrium competitive library screening for tuning inhibitor association rate and specificity toward serine proteases.

Authors:  Itay Cohen; Si Naftaly; Efrat Ben-Zeev; Alexandra Hockla; Evette S Radisky; Niv Papo
Journal:  Biochem J       Date:  2018-04-16       Impact factor: 3.857

5.  Mesotrypsin Signature Mutation in a Chymotrypsin C (CTRC) Variant Associated with Chronic Pancreatitis.

Authors:  András Szabó; Maren Ludwig; Eszter Hegyi; Renata Szépeová; Heiko Witt; Miklós Sahin-Tóth
Journal:  J Biol Chem       Date:  2015-05-26       Impact factor: 5.157

6.  Disulfide engineering of human Kunitz-type serine protease inhibitors enhances proteolytic stability and target affinity toward mesotrypsin.

Authors:  Itay Cohen; Matt Coban; Anat Shahar; Banumathi Sankaran; Alexandra Hockla; Shiran Lacham; Thomas R Caulfield; Evette S Radisky; Niv Papo
Journal:  J Biol Chem       Date:  2019-01-30       Impact factor: 5.157

7.  Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapy.

Authors:  Itay Cohen; Olumide Kayode; Alexandra Hockla; Banumathi Sankaran; Derek C Radisky; Evette S Radisky; Niv Papo
Journal:  Biochem J       Date:  2016-03-08       Impact factor: 3.857

8.  Sequence and conformational specificity in substrate recognition: several human Kunitz protease inhibitor domains are specific substrates of mesotrypsin.

Authors:  Devon Pendlebury; Ruiying Wang; Rachel D Henin; Alexandra Hockla; Alexei S Soares; Benjamin J Madden; Marat D Kazanov; Evette S Radisky
Journal:  J Biol Chem       Date:  2014-10-09       Impact factor: 5.157

9.  Mapping protein selectivity landscapes using multi-target selective screening and next-generation sequencing of combinatorial libraries.

Authors:  Si Naftaly; Itay Cohen; Anat Shahar; Alexandra Hockla; Evette S Radisky; Niv Papo
Journal:  Nat Commun       Date:  2018-09-26       Impact factor: 14.919

10.  The impact of physiological stress conditions on protein structure and trypsin inhibition of serine protease inhibitor Kazal type 1 (SPINK1) and its N34S variant.

Authors:  Ina Buchholz; Felix Nagel; Annelie Klein; Preshit R Wagh; Ujjwal M Mahajan; Andreas Greinacher; Markus M Lerch; Julia Mayerle; Mihaela Delcea
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2019-09-13       Impact factor: 3.036

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.